We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
PURITAN MEDICAL

Download Mobile App




Elevated Levels of Lipoprotein(a) Predict Increased Risk for Developing Cardiovascular Diseases

By LabMedica International staff writers
Posted on 12 Oct 2020
Measurement of the blood biomarker lipoprotein(a) predicts risk of developing cardiovascular disease as well as determination of such standard factors as cholesterol and triglycerides.

Lipoprotein(a) (LPA) is a plasma lipoprotein composed of a low-density lipoprotein (LDL) particle that is covalently linked to apolipoprotein(a) by a disulfide bond. More...
On an equimolar basis, lipoprotein(a) is more atherogenic than LDL because the additional apolipoprotein(a) component may exacerbate atherothrombosis by promoting vascular inflammation and its potential antifibrinolytic activity is associated with inhibition of plasminogen. Lipoprotein(a) levels are 75% to 95% heritable and predominately determined by single-nucleotide variants at the LPA gene and copy number variants specifically in the kringle IV type II domain. Lipoprotein(a) levels greater than 50 milligrams per deciliter are associated with a 30 to 50% greater risk of ASCVD. Individuals with extremely high levels, greater than 200 milligrams per deciliter, may have a three to four times greater risk of ASCVD.

Investigators at Massachusetts General Hospital (Boston, USA) sought to determine if measurement of lipoprotein(a) and/or LPA genetic risk score (GRS) had clinical utility in risk prediction of incident atherosclerotic cardiovascular disease (ASCVD)

For this work, samples were obtained from The UK Biobank, which is a prospective observational study of approximately 500,000 volunteers aged 40 to 69 years who were recruited from 22 sites across the United Kingdom between 2006 and 2010. An LPA GRS was calculated for 374,099 unrelated individuals from this cohort with array-derived genotypes and lipoprotein(a) measures. The mean age of the overall study population was 57.6 years, and 204,355 individuals were female (54.6%). During a median follow-up of 11.1 years, 15, 444 individuals developed an incident ASCVD (peripheral arterial disease, coronary artery disease, myocardial infarction, ischemic stroke, or cardiovascular mortality).

Result revealed that measured lipoprotein(a) and LPA GRS were associated with comparable risk of incident ASCVD events. The LPA GRS did not yield additional prognostic information beyond measured lipoprotein(a), and both measured lipoprotein(a) and LPA GRS yielded modest improvements in the discrimination of ASCVD risk as compared to measurement of traditional risk factors.

"Our work demonstrates that genetic risk scoring of lipoprotein(a) offers risk prediction of atherosclerotic cardiovascular disease that is comparable to directly measured lipoprotein(a)," said senior author Dr. Pradeep Natarajan, a researcher in the division of cardiology and cardiovascular research center at Massachusetts General Hospital. "We learned that genetic determinants of elevated lipoprotein(a) may help identify the most effective medication regimen for cardiovascular disease prevention. Using genetic factors enhances our ability to identify at-risk individuals for cardiovascular disease who could benefit from earlier preventive strategies. At the same time, genetic testing could help identify candidates for clinical trials who are critical to discovering innovative new therapies to address conditions like elevated lipoprotein(a) and related cardiovascular disease risks."

The study was published in the October 6, 2020, online edition of the journal JAMA Cardiology.

Related Links:
Massachusetts General Hospital


Gold Member
Antipsychotic TDM Assays
Saladax Antipsychotic Assays
3-Part Differential Hematology Analyzer
Swelab Alfa Plus Sampler
New
Integrated Biochemical & Immunological System
Biolumi CX8
New
Gold Member
Serological Pipets
INTEGRA Serological Pipets
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








DIASOURCE (A Biovendor Company)

Channels

Hematology

view channel
Image: CitoCBC is the world first cartridge-based CBC to be granted CLIA Waived status by FDA (Photo courtesy of CytoChip)

Disposable Cartridge-Based Test Delivers Rapid and Accurate CBC Results

Complete Blood Count (CBC) is one of the most commonly ordered lab tests, crucial for diagnosing diseases, monitoring therapies, and conducting routine health screenings. However, more than 90% of physician... Read more

Immunology

view channel
Image: A simple blood test could replace surgical biopsies for early detecion of heart transplant rejection (Photo courtesy of Shutterstock)

Blood Test Detects Organ Rejection in Heart Transplant Patients

Following a heart transplant, patients are required to undergo surgical biopsies so that physicians can assess the possibility of organ rejection. Rejection happens when the recipient’s immune system identifies... Read more
Copyright © 2000-2025 Globetech Media. All rights reserved.